{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:37:15Z","timestamp":1772635035869,"version":"3.50.1"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1705","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Nogapendekin alfa inbakicept-pmln (Anktiva \u2013 ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Gu\u00e9rin (BCG) for treatment of patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors.<\/jats:p>","DOI":"10.58347\/tml.2024.1705e","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:06:57Z","timestamp":1718730417000},"page":"105-106","source":"Crossref","is-referenced-by-count":2,"title":["In Brief: Anktiva for Bladder Cancer"],"prefix":"10.58347","volume":"66","member":"37151","published-online":{"date-parts":[[2024,6,24]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:06:57Z","timestamp":1718730417000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1705e"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":0,"journal-issue":{"issue":"1705","published-online":{"date-parts":[[2024,6,24]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1705e","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]}}}